LNP-Delivered Circular IL-23 mRNA and Platinum-MSA-2 Boost T
LNP-Delivered Circular IL-23 mRNA and Platinum-MSA-2 Boost Tumor Immunity
Study Background and Research Question
The stimulator of interferon genes (STING) pathway has emerged as a critical axis in tumor immunotherapy, linking innate and adaptive immune responses and amplifying antitumor immunity. However, clinical translation of STING agonists has been hindered by metabolic instability, limited cellular permeability, and rapid systemic clearance. MSA-2, a next-generation small molecule STING agonist, offers improved stability and permeability, but its single-agent efficacy in vivo remains suboptimal. The reference study (He et al., 2025) investigates whether combining a platinum-modified MSA-2 (MSA-2-Pt) with locally delivered circular IL-23 mRNA encapsulated in lipid nanoparticles (LNP@cIL-23) can synergistically enhance antitumor effects in a murine melanoma model.
Key Innovation from the Reference Study
The central innovation lies in the dual-approach: (1) chemically enhancing the STING agonist (MSA-2) via platinum modification to potentiate DNA-damage signaling and immune activation, and (2) co-delivering circularized IL-23 mRNA using optimized ionizable lipid nanoparticles for targeted, sustained expression within the tumor microenvironment. This pairing directly addresses the challenge of achieving potent, localized, and persistent immune stimulation while minimizing systemic toxicity and innate immune overactivation (He et al., 2025).
Methods and Experimental Design Insights
The research team synthesized a series of ionizable phospholipids to formulate LNP36, an optimized vehicle for delivering circular IL-23 mRNA. Circularization of mRNA was chosen to enhance transcript stability and translation duration. The study utilized the following workflow:
- Preparation and optimization of LNP36 for encapsulation and delivery of circular IL-23 mRNA.
- Chemical modification of MSA-2 with platinum salts to create MSA-2-Pt, leveraging both STING activation and DNA-damage-induced immunogenicity.
- In vivo administration via a single intratumoral (i.t.) injection of LNP36@cIL-23 mRNA, either alone or in combination with MSA-2-Pt, in the B16F10 melanoma mouse model.
- Evaluation of tumor growth inhibition, survival prolongation, and immune cell activation within the tumor microenvironment.
Protocol Parameters
- assay | Intratumoral injection | mouse melanoma model (B16F10) | ensures localized delivery, minimizing systemic cytokine toxicity | [source_type: paper] [source_link: https://doi.org/10.1016/j.mtbio.2025.101446]
- assay | LNP36 encapsulation efficiency | not numerically specified | critical for ensuring high mRNA payload in tumor tissue | [source_type: paper] [source_link: https://doi.org/10.1016/j.mtbio.2025.101446]
- assay | Circular IL-23 mRNA format | full-length, circularized | improves mRNA stability and prolongs in situ protein expression | [source_type: paper] [source_link: https://doi.org/10.1016/j.mtbio.2025.101446]
- assay | Platinum-modified MSA-2 dosing | single i.t. injection | maximizes local STING activation and synergizes with mRNA immunostimulation | [source_type: paper] [source_link: https://doi.org/10.1016/j.mtbio.2025.101446]
- assay | Tumor inhibition and survival | significant improvement vs. controls | demonstrates additive/synergistic immunotherapeutic effect | [source_type: paper] [source_link: https://doi.org/10.1016/j.mtbio.2025.101446]
Core Findings and Why They Matter
The combination of LNP36@cIL-23 mRNA and MSA-2-Pt produced several key results:
- Potent tumor regression and extended survival: The dual therapy resulted in significantly reduced tumor volume and prolonged survival compared to monotherapies or vehicle controls. This effect was attributed to robust immune activation and sustained cytokine expression within the tumor (He et al., 2025).
- Enhanced immune cell infiltration: The treatment induced strong recruitment and activation of CD8+ T cells, natural killer cells, and other effectors central to antitumor immunity.
- Reduced risk of systemic cytokine toxicity: Local (i.t.) delivery limited systemic IL-23 exposure, mitigating adverse events such as cytokine storm or organ toxicity commonly observed with intravenous cytokine therapies.
- Sustained local expression: Circular mRNA and LNP formulation enabled durable IL-23 production in situ, overcoming the short half-life of cytokines and instability of linear mRNA.
Comparison with Existing Internal Articles
Several internal resources provide a framework for understanding the technical underpinnings of capped mRNA delivery, immune evasion, and translation efficiency:
- EZ Cap™ EGFP mRNA (5-moUTP): Advanced Capped mRNA for High-Performance Gene Expression discusses the benefits of Cap 1 structure, 5-methoxyuridine modification, and poly(A) tailing for enhancing mRNA stability, translation, and minimizing innate immune activation. While the referenced study utilizes circular mRNA and LNPs, the core principles of capped and chemically modified mRNA for immune evasion and efficient protein expression remain directly relevant to the IL-23 mRNA strategy [source_type: product_spec] [source_link: https://tamra-azide-5-isomer.com/index.php?g=Wap&m=Article&a=detail&id=16545].
- Innovations in Capped mRNA Delivery further explores how modifications such as 5-moUTP and advanced capping can improve mRNA delivery for gene expression and immune suppression—paralleling the study’s approach to suppress RNA-mediated innate immune activation in the tumor microenvironment.
- Both internal articles support the broader utility of advanced mRNA formats (Cap 1 capping, nucleotide modification, and tail optimization) for translation efficiency assays, in vivo imaging with fluorescent mRNA, and mRNA stability enhancement, as demonstrated in the reference research.
Limitations and Transferability
While the study’s results are compelling, several limitations must be considered:
- Model system constraint: Findings are based on the B16F10 murine melanoma model, which may not fully recapitulate the complexity of human cancers or immune responses.
- LNP/mRNA platform: The circular mRNA and LNP system is optimized for in situ tumor delivery and may require further adaptation for systemic or non-tumor applications.
- Safety profile: While local delivery minimizes systemic exposure, potential for local toxicity, off-target effects, or immunogenicity of the mRNA or LNP components remains.
- Platinum modification: The specific mechanisms by which platinum-modified MSA-2 enhances STING activation are not fully elucidated and may interact variably with other chemotherapeutic agents.
Why this cross-domain matters, maturity, and limitations
The reference study bridges immunotherapy, mRNA drug delivery, and chemical modification strategies, demonstrating that advances in one domain (synthetic mRNA formats and nanoparticle delivery) can directly enhance immune modulation approaches in oncology. This cross-domain synergy is mature at the preclinical proof-of-concept level but will require careful safety and efficacy validation in human subjects. The translational potential is high, though clinical maturity is not yet achieved as per published evidence.
Research Support Resources
For researchers seeking to develop or optimize mRNA delivery for gene expression, translation efficiency assays, or in vivo imaging with fluorescent mRNA, EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016) from APExBIO provides a robust, well-characterized capped mRNA reagent. Its Cap 1 structure, 5-methoxyuridine incorporation, and optimized poly(A) tailing make it suitable for benchmarking mRNA stability, translation efficiency, and suppression of RNA-mediated innate immune activation in both cell-based and in vivo settings [source_type: product_spec] [source_link: https://www.apexbt.com/ez-captm-egfp-mrna-5-moutp.html]. This reagent can support protocol development and troubleshooting for researchers applying similar delivery and expression strategies as outlined in the reference study.